Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951442 | 0.85 | DGAT1 (0.56) | DGAT1CES2CES1MAP2K2MAP2K1 | |
| SCHEMBL290252 | 0.85 | DGAT1 (0.56) | DGAT1CES2CES1MAP2K2MAP2K1 | |
| SCHEMBL29825352 | 0.82 | KDM4E (0.44) | CES2CES1MAP2K2MAP2K1ENPP2 | |
| SCHEMBL733036 | 0.82 | KDM4E (0.44) | CES2CES1MAP2K2MAP2K1ENPP2 | |
| SCHEMBL3786848 | 0.82 | ENPP2 (0.39) | DGAT1ENPP2ALDH1A1CA1CA2 | |
| SCHEMBL24137921 | 0.81 | ALDH1A1 (0.48) | CES2CES1PADI4ENPP2ALDH1A1 | |
| SCHEMBL4847318 | 0.81 | CES2 (0.39) | CES2CES1ENPP2CA1CA2 | |
| SCHEMBL18434017 | 0.78 | ENPP2 (0.33) | PADI4ENPP2ALDH1A1CA1CA2 | |
| SCHEMBL1787715 | 0.77 | ALDH1A1 (0.47) | CASP1ENPP2ALDH1A1CA1CA2 | |
| SCHEMBL237491 | 0.77 | ALDH1A1 (0.43) | CASP1ALDH1A1CA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094932-A | Amide substituted cycloalkyl compound, preparation method and medical application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4172157-B1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| WO-2025077841-A1 | AMIDE-SUBSTITUTED CYCLOALKYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USES THEREOF | 江苏恒瑞医药股份有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12077537-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2013092791-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165437-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GALAPAGOS NV (BE) | 2013-06-27 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| US-8299055-B2 | 8-substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-10-30 | — | — | US | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037108-A1 | AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | DGAT1 1254/4885CES2 1032/4885CES1 913/4885 |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | DGAT1 1013/4885CES2 277/4885CES1 145/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | DGAT1 1013/4885CES2 277/4885CES1 145/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | DGAT1 2190/4885CES2 2017/4885CES1 2193/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | DGAT1 1013/4885CES2 277/4885CES1 145/4885 |
| US-12077537-B2 | Capsid inhibitors for the treatment of HIV | HAVCR2, MAVS, CD4 | DGAT1 3971/4885CES2 197/4885CES1 1903/4885 |
| US-20130165437-A1 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. | GPR84, GPR88, GPR65 | DGAT1 1315/4885CES2 4879/4885CES1 2814/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | DGAT1 2713/4885CES2 3530/4885CES1 1708/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | DGAT1 1013/4885CES2 277/4885CES1 145/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | DGAT1 693/4885CES2 1642/4885CES1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.